Tasly Pharmaceutical Group Co., Ltd.

Pharnext SA is reeling after the failure of its only late-stage asset PXT3003 less than a month after claiming that three companies were vying to partner the potential therapy for Charcot-Marie-Tooth

Bioventure GNT Pharma Co., Ltd has received approval from South Korea's Ministry of Food and Drug Safety to begin a Phase III study with its first-in-class, multi-targeted stroke therapy nelonemdaz,

In June, Tasly Pharmaceutical Co. Ltd. made an official filing for an initial public offering in Hong Kong, the plan being to list Tasly Biologics, a subsidiary of the major Chinese traditional medi

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharma